Reviva Pharmaceuticals Holdings, Inc. (RVPH): Price and Financial Metrics


Reviva Pharmaceuticals Holdings, Inc. (RVPH): $4.76

0.43 (+9.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RVPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RVPH Stock Price Chart Interactive Chart >

Price chart for RVPH

RVPH Price/Volume Stats

Current price $4.76 52-week high $6.10
Prev. close $4.33 52-week low $0.53
Day low $4.38 Volume 253,609
Day high $4.97 Avg. volume 133,935
50-day MA $3.99 Dividend yield N/A
200-day MA $2.51 Market Cap 97.31M

Reviva Pharmaceuticals Holdings, Inc. (RVPH) Company Bio


Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.


RVPH Latest News Stream


Event/Time News Detail
Loading, please wait...

RVPH Latest Social Stream


Loading social stream, please wait...

View Full RVPH Social Stream

Latest RVPH News From Around the Web

Below are the latest news stories about REVIVA PHARMACEUTICALS HOLDINGS INC that investors may wish to consider to help them evaluate RVPH as an investment opportunity.

RedChip CEO Dave Gentry Invited to Join Forbes Business Council

RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council.

Yahoo | January 25, 2023

Reviva Pharmaceuticals Announces Letter to Shareholders

CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows. Dear Fellow Shareho

Yahoo | January 4, 2023

As Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) market cap increased US$11m, insiders who bought last year may be reflecting on buying more

Last week, Reviva Pharmaceuticals Holdings, Inc. ( NASDAQ:RVPH ) insiders, who had purchased shares in the previous 12...

Yahoo | December 16, 2022

Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has announced data from its clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects. The CYP3A4 enzyme is pivotal in helping the body metabolize and remove small foreign molecules and is primarily found in the liver and intestine. Brilaroxazine is a serotonin/dopamine modulator in late-stage clinical development for schizophrenia. A CYP3A4 inhibitor, itraconazole, slight

Yahoo | December 15, 2022

Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine

- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile CUPERTINO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS

Yahoo | December 15, 2022

Read More 'RVPH' Stories Here

RVPH Price Returns

1-mo 12.00%
3-mo 12.00%
6-mo 605.29%
1-year 181.66%
3-year N/A
5-year N/A
YTD 12.00%
2022 47.06%
2021 -66.95%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6816 seconds.